SlideServe
Télécharger Obtenir Pro
Menu
Accueil Pro
Préférences
ApparenceLight Aide et commentaires
© SlideServe · v2026

Study on High Prevalence of Vitamin D Inadequacy Among North American Women with Osteoporosis

mickey avatar
mickey
1 diapositives · 116 Views · Oct 05, 2014

This study examines the prevalence of vitamin D inadequacy in postmenopausal women undergoing osteoporosis treatment. Results show high rates of inadequacy and risk factors associated with low vitamin D levels. The study emphasizes the importance of supplementation and patient education.

Study on High Prevalence of Vitamin D Inadequacy Among North American Women with Osteoporosis - slide 1
01 / 1Study on High Prevalence of Vitamin D Inadequacy Among North American Women with Osteoporosis
1 / 17

Télécharger la présentation

Study on High Prevalence of Vitamin D Inadequacy Among North American Women with Osteoporosis
Une image / un lien ci-dessous est fourni (tel quel) pour télécharger la présentation

Politique de téléchargement : le contenu du site vous est fourni TEL QUEL pour votre information et votre usage personnel ; il ne peut être vendu, concédé sous licence ni partagé sur d’autres sites sans l’accord de son auteur.Le contenu vous est fourni TEL QUEL, pour votre information et votre usage personnel uniquement. Téléchargez la présentation en cliquant sur ce lien. Lors du téléchargement, si vous ne parvenez pas à télécharger une présentation, l’éditeur a peut-être supprimé le fichier de son serveur.Pendant le téléchargement, si vous ne parvenez pas à obtenir une présentation, le fichier a peut-être été supprimé par l’éditeur.

F I N

Plus de contenu associé

Transcription de la présentation

  1. N = 259 / 532 (48.7%) N = 342 / 642 (53.3%) N = 198 / 362 (54.7%) Vitamin D Inadequacy is Highly Prevalent Among North American Women Treated for OsteoporosisMF Holick1, ES Siris2, N Binkley3, MK Beard4, AA Khan5, JT Katzer6, E Chen6, AE de Papp61Boston University Medical Center, Boston, MA, 2Columbia University, NY, NY, 3University of Wisconsin, Madison, WI, 4University of Utah, Salt Lake City, UT, 5McMaster University, Hamilton, ON, 6Merck & Co., Inc., West Point, PA Table 1. BASELINE CHARACTERISTICS INTRODUCTION RESULTS • Vitamin D inadequacy can lead to alterations in calcium and and phosphate homeostasis, secondary hyperparathyroidism, bone loss, osteoporosis, and an increase risk of fractures. • Vitamin D inadequacy may be overlooked by clinicians, potentially leading to a lack of adequate vitamin D supplementation in patients treated for osteoporosis. • This study was designed to evaluate the distribution of serum 25(OH)D concentrations in postmenopausal women currently receiving antiresorptive or anabolic therapies for the treatment of osteoporosis. Vitamin D Inadequacy (<30 ng/ml) Prevalence by Latitude STUDY DESIGN • Cross-sectional observational study conducted from November 2003 to March 2004 • 1554 postmenopausal women from 61 sites in North America • Sites evenly distributed across geographic regions by latitude (>42ºN, Boston, MA, between 35-42ºN, and below 35ºN, Memphis,TN) • Informed consent and past medical history obtained • A single blood sample was collected to assess 25(OH)D, calcium, parathyroid hormone (PTH), phosphate, albumin, creatinine (Cr), magnesium, alkaline phosphatase, and total bilirubin concentrations • A 28 item questionnaire was completed by all study subjects Sites also in Alaska and Hawaii P = NS for test of trend STATISTICAL METHODS Vitamin D Inadequacy (<30 ng/ml): Age Subgroups • 1536 subjects had valid results of serum 25(OH)D • Distribution (mean, standard deviation, median, range, etc.) of serum 25(OH)D was determined, and percent of patients with serum 25(OH)D below various cutpoints was evaluated • Univariate logistic regression models used to assess association between potential risk factors and low 25(OH)D [<30 ng/mL (75 nmol/L)] • Pearson’s correlation coefficient was calculated to assess the relationship between serum 25(OH)D and serum PTH INCLUSION CRITERIA • Postmenopausal women living in North America, currently on antiresorptive or anabolic therapies to treat or prevent osteoporosis • Subjects were >55 years of age and postmenopausal for a minimum of 2 years • Subjects were required to have taken medication to treat or prevent osteoporosis for a minimum of 3 months, including: alendronate, calcitonin, etidronate, raloxifene, risedronate, or teriparatide ENDPOINTS CONCLUSIONS • 25(OH)D concentrations were determined using the Nichols Advantage chemiluminescent assay (normal range 10-68 ng/mL) • Various cutpoints of serum 25(OH)D were used to define vitamin D inadequacy (25(OH)D <9 ng/mL, <15 ng/mL, <20 ng/mL, <25 ng/mL, or <30 ng/mL) • Demographic, dietary, environmental (sun exposure) and health-related variables assessed by subject completed questionnaire • The percent of subjects with biochemical evidence of secondary hyperparathyroidism was determined SUMMARY • Vitamin D inadequacy is highly prevalent amongst postmenopausal women receiving therapy for osteoporosis. • There was a significantly higher prevalence of vitamin D inadequacy among subjects taking less than 400 IU of vitamin D supplementation daily (63%) compared with those who took at least 400 IU daily (45%) (Figure 2). • 206 (16.5%) of subjects had biochemical evidence of secondary hyperparathyroidism. • There was a significant (p<0.001) negative correlation between serum PTH and 25(OH)D; r =-0.3. • Multiple risk factors were associated with Vitamin D inadequacy (p<0.05), including some which are easily modifiable (Table 2). • Up to 52% of North American women currently receiving treatment for osteoporosis have suboptimal 25(OH)D levels. • The prevalence rates of Vitamin D inadequacy are even higher (63%) in those reporting less than 400 IU of Vitamin D supplementation daily. • A high prevalence of Vitamin D inadequacy was seen across all age groups and geographic regions studied. • We advocate the use of Vitamin D supplementation and patient counseling regarding the importance of Vitamin D in all postmenopausal women with osteoporosis.